Distalmotion's Dexter closer to commercialisation

Since its establishment in 2012, Distalmotion has been following its mission to remove the complexity out of robotic surgery to fast track its widespread adoption in minimally invasive surgical care. The company introduced Dexter, a surgical robot designed to allow surgeons and hospitals to access and use surgical robotics technology in healthcare settings and for procedures for which the use of a robot was previously inconceivable.
 
Distalmotion has just concluded a validation study in which 17 surgeons and 16 nurses from leading European hospitals, across urology, gynaecology and general surgery,  performed surgical procedures using the surgical robot to perform tasks including draping, docking, use, switching between laparoscopy and robotics, removal and emergency scenarios. This phase confirmed that Dexter performs as intended and can be used safely. 
 
In a second phase, 2 urologists and 3 general surgeons performed 8 full procedures: 1 Nissen-fundoplication, 1 partial cystectomy, 3 cholecystectomies, 1 radial nephrectomy, 1 partial gastrectomy and 1 sigmoid mobilization. This second phase confirmed Dexter’s full performance for procedures on life-tissues. By confirming that it is safe for use and meets surgeons and nurses requirements, Dexter successful validation brings Distalmotion surgical robot Dexter one-step closer to commercialization.
 
Speaking about Dexter successful validation0, Michael Friedrich, Distalmotion CEO, said, “The Dexter validation is a major milestone towards the go-to-market of Distalmotion’s surgical robot. We are now setting our sight on the final testing and verification before regulatory approval and commercialisation. Today’s announcement is bringing us one step closer to our vision of establishing a new global standard of care allowing everyone to access the benefits of robotic surgery.”